<>
The Richard King Mellon Foundation announced a commitment of up to $25 million on Wednesday to launch Rare Ventures, a Pittsburgh-based initiative designed to accelerate the funding and development of rare disease therapies. According to the foundation, the project utilizes a financial model inspired by the EB Research Partnership, a nonprofit co-founded by Eddie Vedder and his wife Jill to fight the rare genetic skin disease epidermolysis bullosa.
The Self-Sustaining Financial Model
Rare Ventures aims to tackle a major gap in modern healthcare where more than 400 million people worldwide live with a rare disease, yet approximately 95% of those conditions lack approved treatments, according to foundation figures. To bridge this gap, Rare Ventures co-founder Michael Hund stated that the organization will secure philanthropic backing—starting with the Richard King Mellon grant—to fund high-potential research projects in exchange for a financial stake in the work. Hund, who also leads the EB Research Partnership, explained that the platform will reinvest any returns generated from successful treatments back into future research to create a self-sustaining ecosystem.
To unlock the full $25 million commitment from the Richard King Mellon Foundation, Rare Ventures must achieve a series of performance benchmarks over a three-year timeline, according to Hund. The initiative’s operational strategy mirrors the EB Research Partnership, which has raised more than $80 million and advanced multiple clinical trials, including two genetic therapies that recently earned Food and Drug Administration approval.
Pittsburgh Medical Coalition and AI Integration
The startup operates as a collaborative effort involving several prominent Pittsburgh institutions, including the University of Pittsburgh, UPMC Children’s Hospital of Pittsburgh, and Carnegie Mellon University, alongside external partners such as Stanford University. Clinical research and therapy development will heavily center at UPMC Children’s Hospital. Dr. Terence Dermody, chair of pediatrics at the University of Pittsburgh School of Medicine and physician-in-chief at Children’s, noted that the rapid pace of the Rare Ventures collaborative could fundamentally transform how pediatric cures are advanced.
Technology and data analysis form a core pillar of the initiative. Barbara Shinn-Cunningham, dean of the Mellon College of Science at Carnegie Mellon University, stated that university experts will provide technological tools to guide research, utilizing artificial intelligence to detect complex patterns within massive data sets like the human genome that researchers might otherwise miss.
Initial Disease Targets
Rare Ventures is launching its operational pipeline by focusing on seven specific rare conditions. According to Michael Hund, the initial targets comprise:
- Epidermolysis bullosa
- VLCAD deficiency
- PACS1 syndrome
- Autosomal dominant leukodystrophy with autonomic disease
- A specific form of retinitis pigmentosa
- Oculocutaneous albinism type 1A
- Pyruvate dehydrogenase deficiency